近日，恒瑞医药发布公告，该公司收到美国食品药品监督管理局(FDA)关于卡瑞利珠单抗联合甲磺酸阿帕替尼用于不可切除或转移性肝细胞癌患者一线治疗的生物制品许可申请(BLA)的完整回复信(Complete Response Letter )。

Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In animal models, combining macbecin II with immunotherapies, including ...

经观健康 经济观察网讯 ...

Plasmid transfer frequencies measured under laboratory conditions might lead to overestimation of plasmid transfer potential in natural ecosystems. This study assessed differences in the conjugative ...

“It’s clearly what everybody’s been looking for.” In the wake of Summit’s results, drugs like ivonescimab, which block cell signaling via proteins called PD-1 and VEGF, have become the “new shiny ...

Read full article: Woman found dead after man turns gun on himself at Cleveland home Read full article: 2nd suspect charged in shooting that killed grandfather who was buying Happy Meals at west ...

肿瘤细胞的 MFGE8 通过促进细胞外囊泡分选 PD-L1 来诱导抗 pd-1 疗法（αpd-1 ）的耐药性。 与 pd-1/PD-L1 阻断相比，CTLA-4 和 pd-1/PD-L1 双重阻断，并未 ...

Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2025 Earnings Call Transcript February 13, 2025 Applied DNA Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations ...